The national average colorectal screening rate is 39 percent but at Albany Area Primary Health Care it's 60 percent.
Big data is showering its miraculous effects on a range of industries. And the healthcare industry is not left out of the bandwagon. Precision medicine is at the brink of a revolution in individualizing treatment, and healthcare professionals are devising ways to prevent and treat diseases with granularity down to a single patient’s genome.
The flu is a bit of a stealth microbe. Infected people may shed significant amounts of flu virus simply by breathing, scientists have discovered.
One-fifth of patients in a phase 1 study responded to an investigational ERK inhibitor from Merck, bolstering hopes that this type of drug could be used effectively in combination with other cancer drugs. ERK is a cell signal that is believed to drive the growth of many cancers.
A large-scale review of the most common antidepressants has found them all to be superior to placebo in treating major depression, potentially laying to rest questions over their effectiveness.
Cost regulators for NHS treatments in England and Wales are sticking with their position that Eisai’s Halaven should not be funded by the NHS as a second-line of attack against a certain form of breast cancer.
Siemens AG has announced a plan for its Siemens Healthineers business to go public in the first half of the year, according to a company statement. It’s not the first time the German medical imaging and diagnostic business has made its intentions to file an IPO known, but perhaps the company is betting on a more receptive audience in the current market.
Pfizer Inc. (NYSE: PFE) reported financial results for fourthquarter and full-year 2017 and provided 2018 financial guidance.
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced financial results for the fourth quarter and full year of 2017.
Johnson & Johnson today announced sales of $20.2 billion for the fourth quarter of 2017, an increase of 11.5% as compared to the fourth quarter of 2016. Operational sales results increased 9.4% and the positive impact of currency was 2.1%. Domestic sales increased 9.8%. International sales increased 13.5%, reflecting operational growth of 9.0% and a positive currency impact of 4.5%.
Go to Page Go
your submission has already been received.
OK
Please enter a valid Email address!
Submit
The most relevant industry news & insight will be sent to you every two weeks.